| Date | Title | | | 05/21/13 | Alnylam to Webcast Presentation at Deutsche Bank 38th Annual dbAccess Health Care Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 21, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, today announced that management will
present a company overview at the Deutsche Bank 38th Annual
dbAccess Health Care Conference on Wednesday, May 29, 2013 at 2:50 p.m.
ET at The Westin Boston Waterfront Hotel in Boston.
A live audio webcast of the presentation will be available on the News &
Inve... |
|  | | 05/17/13 | Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinate Synthase-1 (ALAS-1) for the Treatment of Porphyria| – RNAi Therapeutics Targeting ALAS-1 Completely Block Production of
Toxic Heme Biosynthesis Intermediates that Cause Symptoms and Disease
Pathology –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 17, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, announced today that it has presented
key pre-clinical proof-of-concept data from its RNAi therapeutic program
targeting aminolevulinate synthase-1 (ALAS-1)... |
| | | 05/15/13 | Alnylam to Webcast Presentation at 2013 UBS Global Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 15, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that management will present a company overview
at the 2013 UBS Global Healthcare Conference on Wednesday, May 22, 2013
at 8:00 a.m. ET at The Sheraton New York Hotel in New York City.
A live audio webcast of the presentation will be available on the News &
Investors section of the compan... |
| | | 05/08/13 | Alnylam to Webcast Presentation at 2013 Bank of America Merrill Lynch Health Care Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 8, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, today announced that management will
present a company overview at the 2013 Bank of America Merrill Lynch
Health Care Conference on Thursday, May 16, 2013 at 8:40 a.m. PT (11:40
a.m. ET) at Encore at the Wynn in Las Vegas.
A live audio webcast of the presentation will be available on the News &
Inv... |
| | | 05/06/13 | Alnylam Pharmaceuticals Reports First Quarter 2013 Financial Results| – Continued to Execute on “Alnylam 5x15” Product Strategy,
Positioning Company for Data-Rich Period over Next Several Months –
– Formed Strategic Alliance with The Medicines Company to Develop and
Commercialize ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the
Treatment of Hypercholesterolemia –
– Completed Successful Public Offering of Stock; Maintained Strong
Balance Sheet with $401 Million in Cash and Expects to End 2013 with
... |
| | | 04/29/13 | Alnylam to Webcast Conference Call Discussing First Quarter 2013 Financial Results| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 29, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, today announced that it will report
financial results for the first quarter ending March 31, 2013 on Monday,
May 6, 2013, after the U.S. financial markets close.
Management will provide an update on the company, discuss first quarter
results, and discuss expectations for the future via conference call on
... |
| | | 04/23/13 | Alnylam to Webcast Presentation at 12th Annual Needham Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 23, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that management will present a company overview
at the 12th Annual Needham Healthcare Conference on Tuesday,
April 30, 2013 at 3:40 p.m. ET at the Westin Grand Central Hotel in New
York City.
A live audio webcast of the presentation will be available on the News &
Investors section... |
| | | 03/18/13 | Alnylam Initiates Phase I Clinical Study for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)|
– ALN-TTRsc is Company’s First Subcutaneously Delivered RNAi
Therapeutic to Enter Clinical Trials –
– Data from Trial Expected Mid-2013 –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 18, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today that it has initiated dosing in its Phase I
clinical trial with ALN-TTRsc, an RNAi therapeutic targeting
transthyretin (TTR) for the tre... |
| | | 03/05/13 | Alnylam to Webcast Presentation at Barclays Global Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that management will present a company overview
at the Barclays Global Healthcare Conference on Tuesday, March 12, 2013
at 10:15 a.m. ET at the Loews Miami Hotel in Miami, Florida.
A live audio webcast of the presentation will be available on the News &
Investors section of the company... |
| | | 02/26/13 | Alnylam to Webcast Presentation at Cowen and Company 33rd Annual Health Care Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 26, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, today announced that management will
present a company overview at the Cowen and Company 33rd
Annual Health Care Conference on Tuesday, March 5, 2013 at 8:40 a.m. ET
at the Boston Marriott Copley Place.
A live audio webcast of the presentation will be available on the News &
Investors section ... |
| | | 02/07/13 | Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results|
– Continued to Execute on “Alnylam 5x15™” Product Strategy with
Positive Clinical Data in Multiple RNAi Therapeutic Programs Including
ALN-TTR02 for Treatment of Transthyretin (TTR)-Mediated Amyloidosis
(ATTR) and ALN-PCS for Treatment of Hypercholesterolemia –
– Advanced Proprietary Conjugate Delivery Platform Enabling
Subcutaneous Delivery of RNAi Therapeutics Towards the Clinic, Including
ALN-TTRsc for Treatment of ATTR, ALN-AT3 for Tr... |
| | | 02/05/13 | Alnylam to Webcast Presentation at Upcoming Investor Conferences| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 5, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that management will present a company overview
at the 15th Annual BIO CEO & Investor Conference on Tuesday,
February 12, 2013 at 2:30 p.m. ET at the Waldorf Astoria in New York
City.
In addition, Alnylam management will present a company overview at the
Leerink Swann Global Hea... |
| | | 02/04/13 | The Medicines Company and Alnylam Form Strategic Alliance to Develop and Commercialize RNAi Therapeutics Targeting PCSK9 for the Treatment of Hypercholesterolemia|
- The Medicines Company Obtains Exclusive Global License to Advance
ALN-PCS RNAi Therapeutic Program -
- Alnylam to Receive $25 Million in Upfront Payment in Addition to
Milestone Payments and Royalties on Product Sales -
- Companies to Host Conference Call Today at 8:30 a.m. ET to Discuss
Collaboration -
PARSIPPANY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 4, 2013--
The
Medicines Company (Nasdaq: MDCO) and... |
| | | 01/31/13 | Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2012 Financial Results| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 31, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that it will report financial results for the
fourth quarter and year ending December 31, 2012, on Thursday, February
7, 2013, after the U.S. financial markets close.
Management will provide an update on the company, discuss fourth quarter
and year-end 2012 results, and discuss expectatio... |
| | | 01/30/13 | Alnylam and Collaborators Publish Results from Phase I Clinical Trial and Extension Study with ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancer|
- Results Published in Cancer Discovery Document Most Comprehensive
Human Experience To Date for RNAi Therapeutics Delivered with Lipid
Nanoparticles (LNPs) -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 30, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, and collaborators announced today the
publication of complete study results from a Phase I trial with ALN-VSP,
a systemically delivered RNA... |
| | | 01/16/13 | Alnylam Pharmaceuticals Announces Exercise of Over-Allotment Option in Public Offering of Common Stock| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 16, 2013--
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a leading RNAi
therapeutics company, today announced that the underwriters of its
previously announced public offering of common stock have exercised
their option to purchase an additional 1,200,000 shares at the public
offering price of $20.13 per share. As a result, the company will issue
a total of 9,200,000 shares in the offering and will receive aggr... |
| | | 01/15/13 | Alnylam Pharmaceuticals Prices Public Offering of Common Stock| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 15, 2013--
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a leading RNAi
therapeutics company, today announced the pricing of an underwritten
registered public offering of 8,000,000 shares of its common stock at a
public offering price of $20.13 per share. All of the shares in the
offering are to be sold by Alnylam. The offering is expected to close on
or about January 22, 2013, subject to the satisfaction of cu... |
| | | 01/14/13 | Alnylam Pharmaceuticals Announces Proposed Public Offering of $125 Million of Common Stock| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 14, 2013--
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a leading RNAi
therapeutics company, today announced that it has commenced an
underwritten public offering of shares of its common stock to raise
aggregate proceeds of approximately $125 million. All of the shares in
the offering are to be sold by Alnylam.
J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as
joint book-... |
| | | 01/06/13 | Alnylam Provides Key 2013 – 2014 Goals for RNAi Therapeutics Pipeline|
- Aims to Advance ALN-TTR02 into Phase III Pivotal Trial in
Transthyretin (TTR)-Mediated Amyloidosis (ATTR) Patients with Familial
Amyloidotic Polyneuropathy (FAP) by Late 2013; Phase II Data Expected in
Mid-2013 -
- Plans to Initiate Exploratory Phase II Study of ALN-TTRsc in ATTR
Patients with Familial Amyloidotic Cardiomyopathy (FAC) by Late 2013;
Phase I Data Expected in Mid-2013 -
- Expects to File Investigational New ... |
| | | 01/03/13 | Alnylam Files Clinical Trial Application to Initiate a Phase I Study for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)|
– Company Expects to Initiate Phase I Study in Early 2013 with Data
in Mid-2013 –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, announced today that it has filed a
Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare
products Regulatory Agency (MHRA) to initiate a Phase I clinical trial
with ALN-TTRsc, an RNAi therapeutic ta... |
| | | 01/02/13 | Alnylam to Webcast Presentation at 31st Annual J.P. Morgan Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 2, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that management will present a company overview
at the 31st Annual J.P. Morgan Healthcare Conference on
Wednesday, January 9, 2013 at 8:00 a.m. PT (11:00 a.m. ET) at the Westin
St. Francis Hotel in San Francisco, Calif. This presentation will
include a review of the company’s goals and guidance.
... |
| |
|
